Royalty Pharma PLC RPRX

Royalty Pharma is a healthcare company that operates as a buyer of biopharmaceutical royalties. It is also a funder of innovation in the biopharmaceutical industry. It is based in New York and was founded in 1996.

The firm works to provide innovative solutions to biopharmaceutical companies, both by pairing up with firms to provide cash for clinical trials and also purchasing royalty rights from pre-existing companies. In total, the company has over 40 commercial products on its royalty list. Some of the company’s investments include AbbVie and J&J’s Imbruvica, Gilead’s HIV franchise, Merck’s Januvia, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Biogen’s Tysabri, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Royalty Pharma is listed on the NASDAQ GS under the ticker RPRX. Stock for the company has been listed on the exchange since June 2020. In April 2021, Royalty Pharma announced the acquisition of Dicerna Pharmaceutical’s royalty interest in OXLUMO in a cash deal for $180m, with an additional $60m contingent on sales. OXLUMO has been approved by both the US Food and Drug Administration and European Medicines Agency for the treatment of primary hyperoxaluria type 1.

Keep up to date on the latest RPRX price changes by adding it to your eToro watchlist.